Compare · EW vs RDUS
EW vs RDUS
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Radius Recycling Inc. (RDUS): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while RDUS operates in Consumer Discretionary - the two are in different parts of the market.
- EW is the larger of the two at $47.58B, about 141.5x RDUS ($336.1M).
- EW has hit the wire 8 times in the past 4 weeks while RDUS has been quiet.
- EW has more recent analyst coverage (25 ratings vs 18 for RDUS).
- Company
- Edwards Lifesciences Corporation
- Radius Recycling Inc.
- Price
- $82.65-1.31%
- $30.00+0.02%
- Market cap
- $47.58B
- $336.1M
- 1M return
- -7.80%
- -
- 1Y return
- +5.33%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 18
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Radius Recycling Inc.
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
Latest EW
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Latest RDUS
- SEC Form 15-12G filed by Radius Recycling Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Radius Recycling Inc.
- Director Hunter Rhonda D returned $1,357,619 worth of shares to the company (45,254 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Chairman, President & CEO Lundgren Tamara L. returned $38,365,800 worth of shares to the company (1,278,860 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP, CFO Gaggini Stefano R. returned $2,708,430 worth of shares to the company (90,281 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP, Chief HR Officer Erich Wilson D returned $1,785,900 worth of shares to the company (59,530 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- EVP & COO Hathhorn Marc E. returned $4,367,430 worth of shares to the company (145,581 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- SVP & President, Recycling P&S Heiskell Steven returned $4,174,800 worth of shares to the company (139,160 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Director Friedman Gregory R returned $562,186 worth of shares to the company (18,740 units at $30.00), closing all direct ownership in the company (SEC Form 4)
- Director Shoemaker Leslie L returned $600,507 worth of shares to the company (20,017 units at $30.00), closing all direct ownership in the company (SEC Form 4)